Sanegene Bio USA Inc. announced that it has received $80 million in a round of funding led by Tencent and YuanBio on December 1, 2023. The transaction included participation from new investors Northern light venture capital, Suzhou Oriza Holdings Co., Ltd., Shenzhen Capital Group Co., Ltd., Xiamen C&D Inc. (SHSE:600153), existing investor Qiming Weichuang Venture Capital Management (Shanghai) Company Limited, TF Capital, K2VC and Beijing Yahui Asset Management Co., Ltd.